Group 1: Industry Overview - Qingdao's Laoshan District has developed a comprehensive biopharmaceutical industry system focusing on marine biomedicine, innovative drugs, high-end medical devices, and modern pharmaceutical services [1] - The marine biopharmaceutical industry in Laoshan has over 130 related enterprises, achieving a scale of 12.3 billion yuan with an 18% year-on-year growth [1] - Laoshan District has been recognized as a national pilot for "Quality Certification Service Strong Enterprises, Strong Chains, Strong Counties," being the only county-level industry to receive this honor in the marine biomedicine sector [1] Group 2: Company Innovations - Qingdao Chenlan Health Industry Group has developed a unique small molecule ClamBPTM peptide using directional enzymatic hydrolysis technology and established the world's first production line for oligopeptides using this technology [1] - Qingdao Chaolan Chuangzhi Information Technology Co., Ltd. has created a differentiated technological barrier in AI-driven drug discovery, applying for 10 invention patents related to AIDD models [1] - Shandong Zhuoye Medical Technology Co., Ltd. has integrated AI medical models with minimally invasive treatment, creating the world's first AI + 3D structured light percutaneous puncture surgical robot [1] Group 3: Future Developments - Qingdao Chenlan Health Industry Group plans to deepen research in high-value utilization of marine active substances and modernization of traditional Chinese medicine, focusing on telomere biology and cellular aging intervention [1] - In the innovative drug sector, Laoshan is accelerating the establishment of leading enterprises like Qiqiao Pharmaceutical, focusing on the development and market launch of new drugs for stroke treatment [1] - Qingdao Huanghai Pharmaceutical Co., Ltd. has established a joint venture for marine innovative drug research and has received clinical approval for several marine new drugs, with plans to continue investing in controlled-release technology and marine innovative drug development [2]